BioAlliance signs Oravig licensing contract with Vestiq
Pursuant to the agreement, BioAlliance will earn up to $44m from Vestiq, the initial $9m corresponding to unconditional payments to be spread over 24 months, and significant royalties
Vertex has signed a definitive agreement to purchase Crinetics Pharmaceuticals in a transaction valued at nearly $10bn, or $8.8bn net of estimated cash acquired.
Proprietary modified-release CTAP101 capsules are designed to raise prohormone serum total 25-hydroxyvitamin D concentrations to targeted levels (at least 30 ng/mL), while avoiding upregulation of a cytochrome P-450